Shares of the South San Francisco, California-based company broke through support and hit a new low.Before the opening bell on Wednesday, Cell Genesys said it was halting VITAL-2, the second of two phase 3 clinical trials of GVAX immunotherapy for prostate cancer, as the trials revealed an imbalance in deaths.Was down about 72%